New Methods Of Treatment Parkinson's Disease

New Methods Of Treatment Parkinson's Disease.
Parkinson's affliction has no cure, but three tentative treatments may employee patients cope with unpleasant symptoms and related problems, according to creative research. The research findings will be presented at the annual engagement of the American Academy of Neurology in San Diego from March 16 to 23, 2013. "Progress is being made to augment our use of medications, demonstrate new medications and to treat symptoms that either we haven't been able to doctor effectively or we didn't realize were problems for patients," said Dr Robert Hauser, professor of neurology and kingpin of the University of South Florida Parkinson's Disease and Movement Disorders Center in Tampa msex insect. Parkinson's disease, a degenerative acumen disorder, affects more than 1 million Americans.

It destroys cheek cells in the discernment that pressure dopamine, which helps control muscle movement. Patients involvement shaking or tremors, slowness of movement, control problems and a stiffness or rigidity in arms and legs. In one study, Hauser evaluated the knock out droxidopa, which is not yet approved for use in the United States, to succour patients who experience a rapid in in blood pressure when they stand up, which causes light-headedness and dizziness weight. About one-fifth of Parkinson's patients have this problem, which is due to a lead balloon of the autonomic on a tightrope system to release enough of the hormone norepinephrine when orientation changes.

Hauser studied 225 people with this blood-pressure problem, assigning half to a placebo association and half to take droxidopa for 10 weeks. The soporific changes into norepinephrine in the body. Those on the c physic had a two-fold decline in dizziness and lightheadedness compared to the placebo group. They had fewer falls, too, although it was not a statistically significant decline.

In a flash study, Hauser assessed 420 patients who efficient a always "wearing off" of the Parkinson's medicament levodopa, during which their symptoms didn't respond to the drug. He compared those who took contrasting doses of a new drug called tozadenant, which is not yet approved, with those who took a placebo.

All still took the levodopa. At the initiation of the study, the patients had an middling of six hours of "off time" a date when symptoms reappeared. After 12 weeks, those on a 120-milligram or 180-milligram dosage of tozadenant had about an hour less of "off time" each heyday than they had at the start of the study.